Revance to Participate in Upcoming Investor Conferences

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

President and Chief Executive Officer, Dan Browne, is scheduled to present at the Cowen and Company 39th Annual Health Care Conference in Boston, MA on Tuesday, March 12 at 9:20am ET.

Chief Financial Officer, Tobin Schilke, is scheduled to present at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 13 at 3:50pm ET.

Interested parties can access the live audio webcasts for both conferences from the Investor Relations section of the company's website at www.revance.com. The webcast replays will be available after the conclusion of the live presentations for approximately 30 days.

About Revance Therapeutics, Inc.

Revance Therapeutics is an emerging Silicon Valley biotechnology leader developing neuromodulators for the treatment of aesthetic and therapeutic conditions. Revance uses a unique proprietary peptide excipient technology to create novel, differentiated therapies. The company’s lead compound, DaxibotulinumtoxinA for Injection (RT002), is in clinical development for a broad range of aesthetic and therapeutic indications, including glabellar lines, cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. The company is advancing a robust pipeline of injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005130/en/

INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
[email protected]
or
Burns McClellan, Inc.:
John Grimaldi, 212-213-0006
[email protected]

or

MEDIA
General Media:
TOGORUN:
Mariann Caprino, 917-242-1087
[email protected]
or
Trade Media:
Nadine Tosk, 504-453-8344
[email protected]

Source: Revance Therapeutics, Inc.

You May Also Be Interested In

• Zedcor Inc. Reports Record Q2 2026 Revenue of $22.7 Million and Adjusted EBITDA of $8.8 Million
• Tenant Inc. and TractIQ Partner to Bring Competitive Intelligence to Self Storage Operators
• Global Water Resources Reports Second Quarter 2026 Results